Genome Editing and Its Applications in Model Organisms

Dongyuan Ma, Feng Liu

State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China

Received 29 October 2015; revised 3 December 2015; accepted 16 December 2015
Available online 4 January 2016

Handled by Xiangdong Fang

KEYWORDS
Genome editing; CRISPR/Cas; Zebrafish; Disease model; Gene therapy

Abstract
Technological advances are important for innovative biological research. Development of molecular tools for DNA manipulation, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regularly-interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas), has revolutionized genome editing. These approaches can be used to develop potential therapeutic strategies to effectively treat heritable diseases. In the last few years, substantial progress has been made in CRISPR/Cas technology, including technical improvements and wide application in many model systems. This review describes recent advancements in genome editing with a particular focus on CRISPR/Cas, covering the underlying principles, technological optimization, and its application in zebrafish and other model organisms, disease modeling, and gene therapy used for personalized medicine.

Introduction
Since the discovery of the DNA double helix in 1953, many basic biological concepts pertaining to the genome, such as gene transcription and translation, genetic code and epigenetic modification, have been established by developing multiple experimental techniques. These include enzymes for in vitro DNA manipulations (such as polymerases, restriction endonucleases, and DNA ligases), recombinant DNA technology, in vitro DNA synthesis, site-specific mutagenesis, and whole-genome sequencing. Nonetheless, site-specific modification within genomes has remained a major challenge.

Genome editing, namely, refers to editing the nucleotides of the genome with engineered nucleases in cultured cells or living organisms. In the past decade, several types of engineered nucleases have been developed, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the recent clustered regularly-interspaced short palindromic repeat (CRISPR) systems. These nucleases, in particular CRISPR systems, immensely facilitate the wide application of genome editing in various biological research fields. More importantly, genome editing holds great promise in potential clinical applications such as gene therapy. In this review, we will briefly describe the features and development of these three editing methods and then mainly focus on the latest CRISPR technology, Science’s 2015 Breakthrough of the Year [1], and its application.

* Corresponding author.
E-mail: liuf@ioz.ac.cn (Liu F).

a ORCID: 0000-0002-9710-5970.
b ORCID: 0000-0003-3228-0943.

Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.

http://dx.doi.org/10.1016/j.gpb.2015.12.001
1672-0229 © 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ZFNs

ZFNs were discovered in 1996 and subsequently employed in genetic engineering experiments with *Drosophila* and mammmalian cells in 2002 [2–4]. Unlike the previously reported approaches relying on DNA base-pair recognition, such as oligonucleotides, reverse splicing, or small molecules, the site-directed ZFNs act through DNA/protein recognition [2,4–7]. ZFNs are composed of a zinc finger-mediated DNA binding domain for DNA recognition and a nuclease activity domain of FokI for DNA cleavage [2]. ZFNs can cause double-strand DNA breaks (DSBs). Subsequently, insertion or deletion at the site of the genomic DSB can be induced by imprecise non-homologous end joining (NHEJ)-mediated repair, whereas point mutations or insertions from oligonucleotide or plasmid donor templates can be introduced by precise homology-directed repair (HDR)-mediated repair [8]. Over the past decade, ZFNs were optimized and widely used in, for example, targeted gene knockout in the genomes of mammalian cells to generate genetically distinct DHFR/−/− cell lines, establishing OCT4-eGFP human embryonic stem cells (hESCs) or targeting *PITX3* in induced pluripotent stem (iPS) cells, and heritable gene disruption in mouse and zebrafish [9–12].

TALENs

Plant pathogen *Xanthomonas* can secret TALEs upon infection of various host species, which facilitate bacterial infection or trigger defense by binding to promoter regions to activate effector-specific genes or R genes of the host plants [13,14]. TALEs recognize specific DNA sequences via DNA-binding domains composed of nearly identical 34-amino acid residues at positions 12 and 13, named repeat-variable diresidues (RVDs), are required for target site specificity [15,16]. Therefore, RVDs have been manipulated to generate the programmable DNA-binding proteins and used for site-directed genome editing [15–19]. Similar to ZFNs, the sequence-independent FokI nuclease, found in *Flavobacterium okeanos*koites, functions as the site-specific nuclease for TALEN assays when the target sites are recognized by different TALEs. Due to the high similarity of TALE recognition sequences, a complicated procedure is required to generate programmable proteins that target specific sites on the genomic DNA, which limits the wide use of TALENs in genome engineering. The presence of extensive identical repeat sequences confers a huge technical challenge to clone repeated TALE arrays for different DNA target sites. To this end, several modified methods have been developed to enable rapid TALE assembly, including the ‘Golden Gate’ platform [20,21], high-throughput solid-phase based sequential ligation systems [22,23], and ligation-independent cloning techniques [24]. For target site recognition, it’s extremely important that the sequence of the TALE binding sites should start with a thymine (T). Moreover, the length of the target site and the spacer between the two TALEN arms are also very important for the formation of the FokI dimer and editing efficiency.

CRISPR/Cas

CRISPR/Cas systems exist in prokaryotes to mediate bacterial adaptive immune defense against viruses or invading nucleic acids, as the first infection experiments showed that CRISPR/Cas confer resistance against lytic phages of *Streptococcus thermophilus* [25]. Brouns et al. found that mature CRISPR RNAs (crRNAs) work with Cas proteins to provide prokaryotes with anti viral defense by interfering with virus proliferation [26]. In 2012, Jinek et al. showed that the dual-RNA structure formed by crRNA and tran-activating crRNA (tracrRNA) is sufficient to direct *Streptococcus pyogenes* type II Cas9 protein (spCas9) to cleave specific target DNA sequences in vitro [27]. *In vitro* DNA cleavage by spCas9 and dual-RNAs reveals the potential of this system for genome editing. Subsequently, the RNA-guided editing tool for mammalian genomes was established using an engineered type II bacterial CRISPR system in 2013 [28,29].

In the CRISPR/Cas system, crRNA–tracrRNA, also referred as the guide RNA (gRNA), recognizes the target sites on the genome, and then recruits Cas9 protein for precise cleavage at specific endogenous genomic loci [28,29]. During this process, synthesis of the gRNA, composed of a specific 20-bp crRNA and the universal tracrRNA, can be driven by a U6 polymerase III promoter in *vivo* or by a phage RNA polymerase, such as T7 RNA polymerase, in *vitro* [29–31]. The first nucleotide of the gRNA target site should be a guanine (G) for U6-directed transcription and two guanines (GG) for T7-directed transcription [28–31]. The most important region for target site selection by the CRISPR/Cas system is the protospacer adjacent motif (PAM) sequence, NGG, which mediates stimulation of the Cas9 nuclease activity [29]. Thus, compared to ZFNs and TALENs, the easy programmability of gRNAs is the most advantageous feature of CRISPR/Cas system (Table 1). Therefore, CRISPR/Cas has been quickly applied to generate mutations in different organisms, to establish various disease models, and for the use in gene correction and therapy [32].

CRISPR/Cas in model organisms

The modified type II CRISPR/Cas, including the human codon–optimized versions of Cas9 and the specific gRNA, was first shown to work efficiently in HEK 293T cells, human leukemia K562 cell line, murine cell lines, and PGPI iPSC cells, using the adeno-associated virus integration site 1 (AAVS1) or empty spiracles homeobox 1 (EMX1) loci as target genes in February 2013 [28,29]. Soon after, in March 2013, the synthesized Cas9 mRNA and gRNA targeting *fumarate hydratase* (fh) were shown to work in *vivo* to induce targeted genetic modifications in zebrafish as efficiently as ZFN and TALENs [33]. A month later, it was reported that Cas9/gRNA efficiently induced biallelic conversion of *etsrp* and *gata5* in zebrafish somatic cells and resulted in the abnormal intersegment vessels and cardinal bifida, respectively, recapitulating the phenotype of *etsrp*−/− and *faum*236a mutants described previously [34]. Later on, CRISPR/Cas-mediated gene editing was used to efficiently disrupt five genes simultaneously in mouse ESCs. Meanwhile, mice with biallelic mutations in *Tet1* and *Tet2*
were generated by co-injecting Cas9 mRNA and gRNA targeting Tet1 and Tet2 into mouse zygotes in May 2013 [30].

In *Drosophila*, efficient mutagenesis of the yellow gene was induced by injecting *Drosophila* embryos with a single guide RNA (sgRNA) targeting the second exon of the gene, and animals carrying stable germline mutations were obtained [35]. CRISPR/Cas9 mediated heritable genome editing in *Caenorhabditis elegans* was established by Calarco’s group in August 2013. Expression of Cas9 protein, together with specific sgRNAs targeting the coding sequences of the *unc-119* and *dpy-13* genes, caused insertion or deletion (indels) in these two genes, and the resulting animals exhibited previously identified phenotypes, such as uncoordinated (Unc) and dumpy (Dpy) [36]. As shown in Figure 1, the CRISPR/Cas system has been rapidly utilized in an increasing number of model organisms, including *Arabidopsis* [37], *Nicotiana benthamiana* [37], rat [38], *Xenopus tropicalis* [39], cynomolgus monkey [40], *Plasmodium falciparum* [41], and even in human tripronuclear zygotes [42].

### CRISPR/Cas in zebrafish

Zebrafish (*Danio rerio*) serves as a classic model organism owing to its unique features, including external fertilization, transparent embryos, high fecundity, and rapid growth. Technologies for genome editing, such as ZFNs, TALENs and CRISPR/Cas, have been applied in zebrafish soon after they were initially reported (Table 2). *fh* was the first gene to be efficiently engineered in zebrafish using CRISPR/Cas [33], and then zebrafish-codon-optimized Cas9 was generated to improve the genome editing efficiency [31,43]. Knock-in of DNA cassettes into the zebrafish genome using CRISPR/Cas9 was carried out by co-injecting a donor plasmid, together with the gRNA and a capped Cas9 mRNA, into one-cell stage embryos. With this convenient approach, specific zebrafish eGFP lines, including Tg(*neurod*:eGFP), Tg(*vsx2*:eGFP), and Tg(*pou4f3*:mGFP), were converted into Gal4 transgenic lines, which facilitated the creation of reporter or loss-of-function alleles in zebrafish [44].

CRISPR/Cas9 was also used to facilitate an HA tag knock-in at the *C13H9orf72* (C9t3) locus using a donor oligonucleotide [45]. It was shown that P2A-EGFP was knocked-in to the endogenous zebrafish *tyrosine hydroxylase* (*th*) to trace *th* positive cells *in vivo* using an intron targeting-mediated and an endogenous gene integrity-maintaining strategy with the CRISPR/Cas system [46]. Zon’s group generated a CRISPR/Cas9 vector system for tissue-specific gene disruption and the *urod* gene was disrupted under the control of different tissue-specific promoters, mimicking human hepatic cutaneous porphyria in zebrafish [47]. Interestingly, multiplex-conditional CRISPR/Cas9-based mutagenesis in zebrafish can be achieved with Cas9 driven by the heat-shock-inducible or tissue-specific promoters and the Golden Gate assembly of sgRNA-expressing cassettes to allow temporally or spatially restricted gene inactivation [48]. In addition, CRISPR/Cas was used *in vivo* for rapid, reverse genetic screening of 48 loci in zebrafish. As a result, two new genes were demonstrated to be involved in electrical synapse formation [49]. Taken together, the application of CRISPR/Cas in zebrafish is becoming more popular, along with the modifications to this technology.
In the meanwhile, zebrafish has become a useful model for technical improvement of CRISPR/Cas system.

**Technological improvement of CRISPR/Cas**

So far, CRISPR/Cas has been used in most of the well-established model organisms. To improve the efficiency and specificity of the CRISPR/Cas system, different codon-optimized versions of Cas9 protein have been generated for different organisms, including human [29], mouse [30,50], and zebrafish [31]. As *in vivo* genome editing in adult organisms is limited by the cargo size of the adeno-associated virus (AAV) vector, Zhang’s group identified shorter Cas9 from *S. thermophilus* LMD-9 (St1Cas9) [28] and *Staphylococcus aureus* (SaCas9). They went further to engineer these Cas9, together with gene specific gRNA, into a single AAV vector to target the cholesterol regulatory gene **Pcsk9** in the mouse liver [51]. They also characterized a new RNA-guided endonuclease named Cas protein 1 of PreFran subtype (Cpf1). Cpf1 utilizes a T-rich PAM and exhibits efficient genome-editing activity in human cells [52]. The studies from Zhang’s lab not only

(Figure 2). In the meanwhile, zebrafish has become a useful model for technical improvement of CRISPR/Cas system.

**Table 2** Genome editing firstly reported in various biological systems and zebrafish

| Technology     | Gene/locus         | First report on genome editing | First report on zebrafish |
|----------------|--------------------|--------------------------------|---------------------------|
| ZFN            | Yellow (y)         | Drosophila                     | Jul, 2002 [3]             | gol                         | Jun, 2008 [11] |
| TALENs         | NTf3 and CCR5      | HEK 293, K562                  | Feb, 2011 [17]            | mikk                        | Aug, 2011 [19] |
| CRISPR/Cas     | AAVS1 locus        | HEK 293, K562, and PGPl iPS cells | Feb, 2013 [29]           | tial1 and gsk3b             | Mar, 2013 [33] |
|                | EMX1               | HEK 293                        | Feb, 2013 [28]            |                             |                |
|                | Th loci            | N2A                             | Feb, 2013 [28]            |                             |                |

**Note:** ZFN, zinc finger nuclease; TALEN, transcription activator-like effector nuclease; CRISPR, clustered regularly-interspaced short palindromic repeat; Cas, CRISPR-associated; NTf3, neurotrophin-3; CCR5, chemokine (C–C motif) receptor 5; AAVS1, adeno-associated virus integration site 1; EMX1, empty spiracles homeobox 1; Th, tyrosine hydroxylase; gol, golden; mikk, TRAF2 and NCK-interacting protein kinase; tial1, T-cell-restricted intracellular antigen-1; gsk3b, glycogen synthase kinase 3 beta.

(Figure 2) **CRISPR/Cas in zebrafish**
showed direct evidence for genome editing in mammalian cells, but also improved the efficiency, utility, and potential applications of the CRISPR/Cas system in broad research fields.

**Efficiency improvement via gDNA modification**

CRISPR/Cas system was also optimized through gRNA modification. Chen’s group developed an optimized CRISPR/Cas system to achieve high rates of biallelic gene disruption in zebrafish F0 populations. Besides the zebrafish codon-optimized Cas9 protein, the sequence of the 3'-end of the crRNA::tracrRNA chimera was modified to GGAUC instead of a string of U residues normally found at the end of gRNA [31]. In following studies, it was found that the use of fewer than 20 nucleotides for gRNA complementarity could minimize off-target effects without sacrificing on-target genome editing efficiencies [53]. Recently, CRISPR subtype Ypest, a modified Cas9 nickase from the bacterium *Pseudomonas aeruginosa*, was used to expand genome targeting sites in human cells and zebrafish [54,55]. In addition, chemically-modified gRNAs were shown to increase the frequency of gene disruption in human primary T cells and CD34+ hematopoietic stem and progenitor cells (hPSCs) without evident toxicity [56]. With the codon-optimized Cas9, the shorter endonucleases, and the modified gRNA and expansion sites, CRISPR/Cas will become a common experimental technique for life science, just like gene cloning.

**Target specificity optimization**

Point mutations in the two nuclease catalytic domains of Cas9, HNH and RuvC, can convert Cas9 into a DNA nickase, which is called Cas9 nickase [27,28]. Moreover, using double Cas9 nickases in combination with the sgRNAs targeting opposite DNA strands of the target sites can cause DSBs with low off-target activity [57]. Quantitative analysis showed that Cas9 nickase could reduce off-target activity by 50–1500 folds in various cell lines [57]. The high target specificity of Cas9 nickase was further verified by Skarnes’ group. They found no detectable NHEJ-induced damage at the reported off-target sites recognized by wild-type Cas9 endonuclease both in mouse embryos and cultured cells [58]. Another successful example for SpCas9 mutant is the recently-reported “enhanced specificity” SpCas9 (eSpCas9) variants generated based on structure-guided protein engineering. eSpCas9 can maintain on-target efficiency and exhibit improved specificity [59].

Similar to ZFNs and TALENs, the smart combination of the inactive Cas9 protein (dCas9) and FokI nuclease was developed by two groups at the same time [55,60]. In the FokI-based CRISPR/Cas system, the FokI nuclease domain is fused to a catalytically-inactive Cas9 protein. After being recruited by two gRNAs, the dimers of the FokI fusion protein mediate sequence-specific DNA cleavage, with a defined spacing and orientation [55,60]. Quantitatively, the specificity of the FokI-based CRISPR/Cas was at least 140 fold higher than that of the wild type Cas9, and even fourfold higher than that of Cas9 nickase at similar endogenous off-target loci [60]. Recently, it was shown that SpCas9 can be modified with altered PAM specificity in zebrafish embryos and human cells. The specificity of a SpCas9 variant containing non-canonical NAG and NGA was increased in human cells [61]. In summary, both Cas9 nickase and FokI-based CRISPR/Cas can improve DNA cleavage specificity with lower off-target activity, which makes highly specific genome-wide editing much easier.

**Inducible CRISPR system**

Conditional mutagenesis is often necessary to uncover the mechanism of gene function. Efforts to modify the efficiency and specificity of the CRISPR/Cas system also involve control of Cas9 nuclease activity in a spatial and temporal manner. Firstly, the inducible CRISPR (iCRISPR) system, composed of doxycycline-regulated Cas9 and a specific gRNA, was developed for genome editing in human pluripotent stem cells (hPSCs) and adult mice, and for generation of stage-specific inducible gene knockouts [62–64]. In addition, low copy expression of the rapamycin-inducible split-Cas9, composed of Cas9(N)-FK506 binding protein 12 (FKBP) and Cas9(C)-FKBP, can induce mutations at EMX1 loci, while split dCas9-VP64 can mediate inducible transcription activation in HEK293FT cells [65]. Furthermore, photoactivatable Cas9 (paCas9) that responds to blue light irradiation was generated on the basis of split-Cas9 and photo-inducible dimerization domains named Magnets. paCas9 has been exploited and validated for efficient genome editing in human cells [66]. The greatest advantage of this system is its spatiotemporal and reversible feature, making it a potential alternate to the Cre-loxP system in generating conditional knockouts *in vivo*. Moreover, paCas9 and specific gRNAs targeting different endogenous genes may facilitate multiple gene knock-outs *in vivo* in a spatiotemporal manner, which would be much easier than other systems.

**Gene regulation by dCas9 fused with effector domains**

In addition to genome editing, a modified form of Cas9 that lacks the endonuclease activity, dead Cas9 (dCas9), was first shown to regulate endogenous gene expression in *Escherichia coli* and mammalian cells [67]. This system, called CRISPR interference (CRISPRi), can repress the expression of targeted genes. Soon after, dCas9 was fused to effector domains with distinct regulatory functions for stable and efficient repression or activation at the transcriptional level in human and yeast cells [68]. The specificity of CRISPRi-mediated transcriptional regulation was determined solely by the co-expressed short gRNA that can recognize the endogenous target gene. dCas9-KRAB or dCas9-VP16 was used to alter expression of the endogenous dpy-5 and dbl-1 in *C. elegans* or *fgf8a* and *foxil* in zebrafish embryos, respectively [69]. More importantly, the modified photoactivatable dCas9 (padCas9) system can reversibly control spatiotemporal expression of endogenous genes [66].

Cas9 is an RNA-guided DNA endonuclease, which requires a short DNA sequence named PAM for binding and catalysis. It was found, however, that Cas9 can also bind to single-stranded RNA (ssRNA) in the presence of specially-designed PAM-presenting oligonucleotides (PAMmers) and a matching gRNA, leading to site-specific cleavage of ssRNA targets while ignoring the corresponding DNA sequences [70]. In addition, dCas9 with specifically designed 5’-extended PAMmers and...
gRNA can target non-PAM sites on GADPH mRNA, allowing this mRNA to be purified from HeLa cells in a tagless manner [70]. Therefore, programmable RNA recognition by CRISPR/Cas can be used as a candidate approach for specific endogenous mRNA isolation, analysis, and manipulation in the absence of affinity tags [70]. The dCas9 not only expands the application of CRISPR/Cas to areas other than genome editing, but also provides a candidate method for spatiotemporal and reversible gene regulation in vivo, with the help of helperCas9 controlled by blue light irradiation.

**Generation of disease models using CRISPR/Cas**

In addition to site-specific modifications in the genomes, TALENs and CRISPR/Cas also have potential applications in disease models and gene correction. First, human stem cell-based disease models were generated using TALENs, and different disease-related genes were analyzed, including APOB for human hepatitis C virus (HCV) replication, SORT1 (encoding sortilin) for ApoB secretion in hepatocytes, insulin resistance in adipocytes and motor neuron death, and PLIN1 for lipolysis in adipocytes [71]. More importantly, heritable disease models have been easily generated. For instance, lentivirus-delivered sgRNA:Cas9 genome editing was used to generate mouse models of myeloid malignancy by modifying five genes in mouse hematopoietic stem cell (HSC) [72]. And a cancer model was also generated using the CRISPR/Cas system by targeting tumor suppressor genes pten and p53 in liver [73]. As for zebrafish disease models, a rps19 null mutant was generated using TALENs to reproduce the erythroid defects of Diamond–Blackfan anemia (DBA) [74]. Recently, human hepatic cutaneous porphyria was mimicked by a tissue-specific gene inactivation system resulting from disruption of the umber gene using a different tissue-specific promoter [47].

Using CRISPR/Cas system, Liu’s group generated a series of mutations in the blood development related genes of zebrafish, including ncor2 [75], runx1, runx3, rac2, and klf6a (unpublished data), that could be used to model human hematological diseases, including bone marrow failure, anemia, and myelodysplasia syndrome (MDS). The Zebrafish All Genes KO Consortium for Chromosome 1 (ZAKOC) has been established with the efforts of nearly all the zebrafish labs in China since June 2013. This project would accumulate zebrafish mutant resources for basic sciences and also for disease modeling.

**Gene therapy on clinical mutations and disease models**

Gene therapy, based on therapeutic delivery of nucleic acid polymers into patient, is an innovative method that has generated much controversy. Development of CRISPR/Cas and TALENs makes gene therapy more feasible and easier in the treatment of diseases. CRISPR/Cas was firstly used for efficient correction of disease-related genes in mouse and intestinal stem cells of a cystic fibrosis (CF) patient at the end of 2013 [76]. Clevers’s group cultured intestinal (LI) stem cells from CF patients homozygous for the most common cystic fibrosis transmembrane conductance regulator (CFTR) mutations and used CRISPR/Cas-mediated homologous recombination to correct the CFTR locus. Their data indicated that the corrected allele could be detected and was confirmed to be functional [77]. A single nucleotide deletion in exon 3 of the Crygc gene in mice leads to the generation of a stop codon at the 76th amino acid residue. Mice with the resulting dominant gene mutation serve as a model of dominant cataract disorder [76,77]. Li’s group showed that the mutation in Crygc can be corrected at the organismal level through HDR, by co-injecting Cas9 mRNA, together with a specific gRNA targeting the mutant allele with exogenously-supplied oligonucleotide, into zygotes [76]. Further analysis showed that the mouse carrying the corrected mutation was fertile and able to transmit the modified DNA sequence to its progeny [76]. To date, there are a number of disease models reported to be corrected successfully using CRISPR/Cas-mediated homologous recombination, such as the Fih mutation in mouse hepatocytes [78] and the mdr mutation in the mouse model for Duchene muscular dystrophy (DMD) [79].

β-thalassemia, caused by mutations in the adult β-globin gene, is one of the most common genetic diseases worldwide [80]. Pan’s group efficiently generated integration-free β-thalassemia iPSC cells from the cells of patients and corrected β-globin gene (HBB) mutations in situ using TALENs with a donor template harboring the entire wild type β-globin gene [80]. Further study showed that the gene-corrected β-thalassemia iPSC cells, which was phenotype similar to the patient, were developed and used in the histone modification model. Later on, the HBB mutations in patient-derived iPSCs was also efficiently corrected using CRISPR/Cas9 combined with the piggyBac transposon without leaving a residual footprint. The corrected iPSC cells were differentiated into erythroblasts with restored expression of HBB [81]. Fanconi anemia is another blood disease in which gene correction was attempted. The FANCC c.456 + 4A > T mutation in patient-derived fibroblasts was corrected using CRISPR/Cas9 with a donor plasmid containing a floxed puromycin and FANCC cDNA flanked with arms that were homologous to the FANCC locus [82].

**Conclusion and perspective**

New tools for DNA manipulation, including TALENs and CRISPR/Cas, not only make site-specific modifications in the genomes much easier, but also revolutionize the classical approaches for determining gene function due to their target site specificity, flexible design, and ease of operation. Traditional forward genetics approaches can generate mutants with the desired phenotypes; however, the subsequent gene mapping is very complicated, and it is not feasible to perform large-scale genetic screens in some model organisms. Reverse genetics by gene targeting usually employs ESCs, which are limited to a few model systems, and the process is time-consuming. The newly-emerging technologies for genome editing can, in principal, target any gene of interest; therefore, specific modifications or targeted gene knockouts can be easily obtained in model organisms. So far, CRISPR/Cas has been quickly optimized and applied to most of the current model systems, and even in the human triploid nuclear zygotes (Figure 1).

The CRISPR/Cas system has been continuously improved from different angles, including efficiency, specificity,
spatiotemporal control, and endonuclease inactivation (Table 3). Until now, the CRISPR/Cas system not only improves basic research but also has potential applications in gene therapy through gene repair, gene disruption, and programmable RNA targeting [32]. However, there are also some disadvantages and controversial issues, for example, the off-target effect. To solve this problem, the chemically-modified gRNAs, Cas9 nickase, FokI-based CRISPR/Cas, and eSpCas9 can be harnessed to reduce off-target and improve the specificity.

For the clinical application of CRISPR/Cas in future, many points should be considered. The first question is how to guarantee the efficiency. In spite of the improvements on Cas9 and the gRNAs, the low efficiency of HDR after Cas9-mediated DNA cutting is a challenge. Importantly, it has been shown that inhibiting NHEJ-mediated repair enhances HDR for the insertion of precise genetic modifications by the inhibitor, Scr7 targeted DNA ligase IV, or by key molecules involved in gene silencing [83,84]. The next question is how to deliver Cas9 and gRNAs to cells, especially to adult tissues. Fortunately, the shorter form of Cas9 in the AAV vector, nucleofection, cell-penetrating peptides, and the inducible Cas9 can be harnessed to reduce off-target and improve the specificity.

For the clinical application of CRISPR/Cas in future, many points should be considered. The first question is how to guarantee the efficiency. In spite of the improvements on Cas9 and the gRNAs, the low efficiency of HDR after Cas9-mediated DNA cutting is a challenge. Importantly, it has been shown that inhibiting NHEJ-mediated repair enhances HDR for the insertion of precise genetic modifications by the inhibitor, Scr7 targeted DNA ligase IV, or by key molecules involved in gene silencing [83,84]. The next question is how to deliver Cas9 and gRNAs to cells, especially to adult tissues. Fortunately, the shorter form of Cas9 in the AAV vector, nucleofection, cell-penetrating peptides, and the inducible Cas9 have been developed, which will provide candidate approaches for gene therapy in adult [85,86]. Finally, the most controversial question is whether CRISPR/Cas can be used in humans ethically and safely. As Jennifer Doudna, a pioneer of CRISPR/Cas technology, pointed out, with the rapid development of this technology and its wide application, the philosophical and ethical ramifications for altering genomes, especially on the modification of human germ cells and embryos should be very cautious, and an international guideline on the proper use of genome editing should be abided by the entire field [87,88]. Overall, this ethical issue needs to be addressed by scientists and society before CRISPR/Cas can be used in clinical gene therapy and that CRISPR/Cas system also needs to be optimized on various aspects to improve the efficiency and specificity.

Competing interests

The authors have no conflicts of interest to declare.

Acknowledgments

We thank Dr. Bo Zhang for critical reading of this manuscript. This work was supported by grants from the National Basic Research Program of China (Grant Nos. 2010CB945300 and 2011CB943900), the National Natural Science Foundation of China (Grant Nos. 31271570, 31425016, 31370030, and 81530004), and the Strategic Priority Research Program of the Chinese Academy of Sciences (Grant No. XDA01010110).

References

[1] Travis J. Making the cut. Science 2015;350:1456–7.
[2] Bibikova M, Beumer K, Trautman JK, Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003;300:764.
[3] Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002;161:1169–75.
[4] Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 1996;93:1156–60.
[5] Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB. Regulation of gene expression by small molecules. Nature 1997;387:202–5.
[6] Yang J, Zimmerly S, Perlman PS, Lambowitz AM. Efficient integration of an intron RNA into double-stranded DNA by reverse splicing. Nature 1996;381:332–5.
[7] Galj T, Gersbach CA, Barbas 3rd CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31:397–405.
[9] Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A 2008;105:5809–14.

[10] Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009;27:851–7.

[11] Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008;26:702–8.

[12] Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. Nat Rev Genet 2005;6:507–12.

[13] Gu K, Yang B, Tian D, Wu L, Wang D, Sreekala C, et al. R gene expression induced by a type-III effector triggers disease resistance in rice. Nature 2005;435:1122–5.

[14] Romer P, Hahn S, Jordan T, Strauss T, Bonas U, Lahaye T. Plant pathogen recognition mediated by promoter activation of the pepper B3 resistance gene. Science 2007;318:645–8.

[15] Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Lahaye T. Plant pathogen recognition mediated by promoter activation of the pepper B3 resistance gene. Science 2007;318:645–8.

[16] Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009;326:1509–12.

[17] Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011;29:143–8.

[18] Zhang F, Cong L, Lodato S, Kosuri S, Church GM, Arlotta P. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 2011;29:149–53.

[19] Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 2011;29:699–700.

[20] Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011;39:e82.

[21] Cermak T, Starker CG, Voytas DF. Efficient design and assembly of custom TALENs using the Golden Gate platform. Methods Mol Biol 2015;1239:133–59.

[22] Briggs AW, Rios X, Chari R, Yang L, Zhang F, Mali P, et al. Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res 2012;40:e117.

[23] Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012;30:460–5.

[24] Schmid-Burgk JL, Schmidt T, Kaiser V, Honing K, Hornung V. A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes. Nat Biotechnol 2013;31:76–81.

[25] Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007;315:1709–12.

[26] Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 2008;321:960–4.

[27] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816–21.

[28] Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819–23.

[29] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.

[30] Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153:910–8.

[31] Joung JK, Wente SR, Chen W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci U S A 2013;110:13904–9.

[32] Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR–Cas9. Science 2014;346:1258096.

[33] Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, et al. Efficient genome editing in zebrafish using a CRISPR–Cas system. Nat Biotechnol 2013;31:227–9.

[34] Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, et al. Genome editing with RNA-guided Cas9 nuclelease in zebrafish embryos. Cell Res 2013;23:465–72.

[35] Basset AR, Tiffert C, Ponting CP, Liu JL. Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 2013;4:220–8.

[36] Friedland AE, Tzur YB, Esvelt KM, Colaiacovo MP, Church GM, Calarco JA. Heritable genome editing in C. elegans via a CRISPR–Cas9 system. Nat Methods 2013;10:741–3.

[37] Li JF, Norville JE, Aach J, McCormack M, Zhang D, Bush J, et al. Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol 2013;31:688–91.

[38] Hu X, Chang N, Wang X, Zhou F, Zhou X, Zhu X, et al. Heritable gene-targeting with gRNA/Cas9 in rats. Cell Res 2013;23:1322–5.

[39] Nakayama T, Fish MB, Fisher M, Oomen-Hajagos J, Thomsen GH, Grainger RM. Simple and efficient CRISPR/Cas9-mediated targeted mutagenesis in Xenopus tropicalis. Genesis 2013;51:835–43.

[40] Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al. Generation of gene-modified cycnomolus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 2014;156:836–43.

[41] Wagner JC, Platt RJ, Goldfuss SJ, Zhang F, Niles JC. Efficient CRISPR–Cas9-mediated genome editing in Plasmodium falciparum. Nat Methods 2014;11:915–8.

[42] Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripornuclear zygotes. Protein Cell 2015;6:363–72.

[43] Liu D, Wang Z, Xiao A, Zhang Y, Li W, Zu Y, et al. Efficient gene targeting in zebrafish mediated by a zebrafish-codon-optimized cas9 and evaluation of off-targeting effect. J Genet Genomics 2014;41:43–6.

[44] Auer TO, Duroyre K, De Cian A, Concordet JP, Del Bene F. Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res 2014;24:142–53.

[45] Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass C, et al. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 2013;140:4982–7.

[46] Li J, Zhang BB, Ren YG, Gu SY, Xiang YH, Du JL. Intron targeting-mediated and endogenous gene integrity-maintaining knockin in zebrafish using the CRISPR/Cas9 system. Cell Res 2015;25:634–7.

[47] Ablain J, Durand EM, Yang S, Zhou Y, Zon LI. A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. Dev Cell 2015;32:756–66.

[48] Yin L, Maddison LA, Li M, Kara N, LaFave MC, Varshney GK, et al. Multiplex conditional mutagenesis using transgenic expression of Cas9 and sgRNAs. Genetics 2015;200:431–41.
Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 2013;23:720–3.

Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186–91.

Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Esletzbichler P, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR–Cas system. Cell 2015;163:759–71.

Fu Y, Sander JD, Reyon D, Casgeo VM, Joung JK. Improving CRISPR–Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 2014;32:279–84.

Qin W, Liang F, Feng Y, Bai H, Yan R, Li S, et al. Expansion of CRISPR/Cas9 genome targeting sites in zebrafish by Cas94-based RNA processing. Cell Res 2015;25:1074–7.

Tsai SQ, Wymeckens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 2014;32:569–76.

Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, et al. Chemically modified guide RNAs enhance CRISPR–Cas9 genome editing in human primary cells. Nat Biotechnol 2015;33:985–9.

Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013;154:1380–9.

Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al. Efficient genome modification by CRISPR–Cas9 nickase with minimal off-target effects. Nat Methods 2014;11:399–402.

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016;351:84–8.

Gungliger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 2014;32:577–82.

Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. Engineered CRISPR–Cas9 nucleases with altered PAM specificities. Nature 2015;523:481–5.

Zhu Z, Gonzalez F, Huangfu D. The iCRISPR platform for rapid genome editing in human pluripotent stem cells. Methods Enzymol 2014;546:215–50.

Gonzalez F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV, et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 2014;15:215–26.

Dow LE, Fisher J, O’Rourke KP, Muley A, Kastenhuber ER, Livshits G, et al. Inducible in vivo genome editing with CRISPR–Cas9. Nat Biotechnol 2015;33:390–4.

Zetsche B, Volz SE, Zhang F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol 2015;33:139–42.

Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable CRISPR/Cas9 for optogenetic genome editing. Nat Biotechnol 2015;33:755–60.

Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013;152:1173–83.

Gilbert LA, Larson MH, Morsey I, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013;154:442–51.

Long L, Guo H, Yao D, Xiong K, Li Y, Liu P, et al. Regulation of transcriptionally active genes via the catalytically inactive Cas9 in C. elegans and D. rerio. Cell Res 2015;25:638–41.

O’Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 2014;516:263–6.

Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013;12:238–51.

Heckl D, Kowalczyk M, Yudovich D, Belizaire R, Parham RV, McConkey ME, et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR/Cas9 genome editing. Nat Biotechnol 2014;32:941–6.

Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014;514:380–4.

Zhang Y, Ear J, Yang Z, Morimoto K, Zhang B, Lin S. Defects of protein production in erythroid cells revealed in a zebrafish Diamond–Blackfan anemia model for mutation in RPS19. Cell Death Dis 2014;5:e1352.

Wei Y, Ma D, Gao Y, Zhang C, Wang L, Liu F. Norco2 is required for hematopoietic stem cell emergence by inhibiting Fos signaling in zebrafish. Blood 2014;124:1578–85.

Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, et al. Cas9-mediated sequestration of mouse via use of CRISPR–Cas9. Cell Stem Cell 2013;13:659–62.

Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013;13:653–8.

Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014;32:551–3.

Long C, McAnally JR, Shelson JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 2014;345:1184–8.

Ma N, Liao B, Zhang H, Wang L, Shan X, Yue Y, et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. J Biol Chem 2013;288:34671–9.

Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014;24:1526–33.

Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, et al. Fanconia anemia gene editing by the CRISPR/Cas9 system. Hum Gene Ther 2015;26:114–26.

Chu VT, Weber T, Wefers B, Wurst S, Sander S, Rajewsky K, et al. Increasing the efficiency of homology-directed repair for CRISPR–Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 2015;33:543–8.

Maruyama T, Dougan SK, Truttman MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR–Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 2015;33:538–42.

Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014;24:1012–9.

Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalaparra L, Lee SK, Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014;24:1020–7.

Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, et al. Biotechnology: A prudent path forward for genomic engineering and germline gene modification. Science 2015;348:36–8.

Doudna J. Genome-editing revolution: my whirlwind year with CRISPR. Nature 2015;528:469–71.

344 Genomics Proteomics Bioinformatics 13 (2015) 336–344